Free Trial
→ Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid (From Altimetry) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bay National Co. stock logo
BAYN
Bay National
$0.01
$0.01
$0.01
▼
$0.01
N/A1.56510 shs10,200 shs
GENFIT S.A. Unsponsored ADR stock logo
GNFT
GENFIT
$4.85
$4.47
$3.41
▼
$4.93
$242.62M1.097,393 shsN/A
MorphoSys AG stock logo
MOR
MorphoSys
$18.96
$18.96
$4.18
▼
$19.50
$2.86B1.21.02 million shsN/A
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$147.01
-0.2%		$144.91
$82.01
▼
$156.92
$363.15B0.2110.60 million shs6.20 million shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bay National Co. stock logo
BAYN
Bay National
0.00%0.00%0.00%0.00%0.00%
GENFIT S.A. Unsponsored ADR stock logo
GNFT
GENFIT
0.00%0.00%0.00%0.00%+18.29%
MorphoSys AG stock logo
MOR
MorphoSys
0.00%0.00%0.00%0.00%0.00%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
+3.87%+3.37%+1.83%+15.51%+73.86%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bay National Co. stock logo
BAYN
Bay National
$0.01
$0.01
$0.01
▼
$0.01
N/A1.56510 shs10,200 shs
GENFIT S.A. Unsponsored ADR stock logo
GNFT
GENFIT
$4.85
$4.47
$3.41
▼
$4.93
$242.62M1.097,393 shsN/A
MorphoSys AG stock logo
MOR
MorphoSys
$18.96
$18.96
$4.18
▼
$19.50
$2.86B1.21.02 million shsN/A
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$147.01
-0.2%		$144.91
$82.01
▼
$156.92
$363.15B0.2110.60 million shs6.20 million shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bay National Co. stock logo
BAYN
Bay National
0.00%0.00%0.00%0.00%0.00%
GENFIT S.A. Unsponsored ADR stock logo
GNFT
GENFIT
0.00%0.00%0.00%0.00%+18.29%
MorphoSys AG stock logo
MOR
MorphoSys
0.00%0.00%0.00%0.00%0.00%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
+3.87%+3.37%+1.83%+15.51%+73.86%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bay National Co. stock logo
BAYN
Bay National
0.00
N/AN/AN/A
GENFIT S.A. Unsponsored ADR stock logo
GNFT
GENFIT
0.00
N/AN/AN/A
MorphoSys AG stock logo
MOR
MorphoSys
0.00
N/AN/AN/A
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
2.63
Moderate Buy$151.923.34% Upside

Current Analyst Ratings Breakdown

Latest MRK, BAYN, MOR, and GNFT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/12/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetNeutral$125.00 ➝ $145.00
10/12/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access to unlock brokerage rankings
Lower Price TargetSector Perform$150.00 ➝ $145.00
10/8/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetNeutral$120.00 ➝ $145.00
10/7/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access to unlock brokerage rankings
Lower Price TargetOverweight$179.00 ➝ $177.00
10/5/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetOverweight$150.00 ➝ $165.00
9/29/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Scotiabank logo
Scotiabank
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetSector Outperform$155.00 ➝ $180.00
9/23/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetHold$137.00 ➝ $155.00
9/11/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Berenberg Bank logo
Berenberg Bank
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetHold$127.00 ➝ $137.00
9/10/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
HSBC Holdings plc logo
HSBC
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetBuy$150.00 ➝ $172.00
9/9/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Leerink Partners logo
Leerink Partners
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetOutperform$127.00 ➝ $161.00
(Data available from 10/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bay National Co. stock logo
BAYN
Bay National
N/AN/AN/AN/AN/AN/A
GENFIT S.A. Unsponsored ADR stock logo
GNFT
GENFIT
$41.52M5.84$0.07 per share69.34$1.50 per share3.23
MorphoSys AG stock logo
MOR
MorphoSys
$238.28M11.99N/AN/A$0.35 per share54.17
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$66.57B5.45$11.83 per share12.43$21.22 per share6.93
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bay National Co. stock logo
BAYN
Bay National
N/AN/AN/AN/AN/AN/AN/AN/AN/A
GENFIT S.A. Unsponsored ADR stock logo
GNFT
GENFIT
$1.63MN/AN/AN/AN/AN/AN/AN/AN/A
MorphoSys AG stock logo
MOR
MorphoSys
-$205.35M-$3.48N/AN/AN/A-226.79%-694.31%-22.55%N/A
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$18.25B$1.25117.7515.866.564.77%16.73%6.13%10/29/2026 (Estimated)

Latest MRK, BAYN, MOR, and GNFT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
10/29/2026Q3 2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$2.09N/AN/AN/A$17.27 billionN/A
8/4/2026Q2 2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
-$0.26-$0.13+$0.13-$0.54$16.37 billion$16.61 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Bay National Co. stock logo
BAYN
Bay National
N/AN/AN/AN/AN/A
GENFIT S.A. Unsponsored ADR stock logo
GNFT
GENFIT
N/AN/AN/AN/AN/A
MorphoSys AG stock logo
MOR
MorphoSys
N/AN/AN/AN/AN/A
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$3.402.31%+5.75%272.00%14 Years

Latest BAYN, MRK, MOR, and GNFT Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/29/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
quarterly$0.852.36%9/15/20269/15/202610/7/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bay National Co. stock logo
BAYN
Bay National
N/AN/AN/A
GENFIT S.A. Unsponsored ADR stock logo
GNFT
GENFIT
0.09
3.74
3.74
MorphoSys AG stock logo
MOR
MorphoSys
4.98
1.38
1.38
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
1.22
1.32
1.10

Institutional Ownership

CompanyInstitutional Ownership
Bay National Co. stock logo
BAYN
Bay National
N/A
GENFIT S.A. Unsponsored ADR stock logo
GNFT
GENFIT
2.24%
MorphoSys AG stock logo
MOR
MorphoSys
18.38%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
76.07%

Insider Ownership

CompanyInsider Ownership
Bay National Co. stock logo
BAYN
Bay National
17.76%
GENFIT S.A. Unsponsored ADR stock logo
GNFT
GENFIT
4.20%
MorphoSys AG stock logo
MOR
MorphoSys
0.05%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
0.17%
CompanyEmployeesShares OutstandingFree FloatOptionable
Bay National Co. stock logo
BAYN
Bay National
N/AN/AN/ANot Optionable
GENFIT S.A. Unsponsored ADR stock logo
GNFT
GENFIT
12050.03 million47.92 millionNot Optionable
MorphoSys AG stock logo
MOR
MorphoSys
730150.62 million150.55 millionNot Optionable
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
75,0002.47 billion2.46 billionOptionable

Recent News About These Companies

Curated Wealth Partners LLC Sells 127,541 Shares of Merck & Co., Inc. $MRK
 |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-curated-wealth-partners-llc-sells-127541-shares-of-merck-co-inc-mrk-2026-10-15/
AMGN vs. MRK: Which Pharma Giant's Dividend Actually Has Room to Grow
 |  247wallst.comhttps://247wallst.com/investing/2026/10/15/amgn-vs-mrk-which-pharma-giants-dividend-actually-has-room-to-grow/?utm_source=snapi
Here is What to Know Beyond Why Merck & Co., Inc. (MRK) is a Trending Stock
 |  zacks.comhttps://www.zacks.com/stock/news/3008141/here-is-what-to-know-beyond-why-merck-co-inc-mrk-is-a-trending-stock?cid=cs-stocknewsapi-ft-fundamental_analysis|most_searched_stocks-3008141
Here is What to Know Beyond Why Merck & Co., Inc. (MRK) is a Trending Stock
October 15 at 9:22 AM  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/know-beyond-why-merck-co-120008448.html
VMS Asset Management Limited Makes New Investment in Merck & Co., Inc. $MRK
October 15 at 7:35 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-vms-asset-management-limited-makes-new-investment-in-merck-co-inc-mrk-2026-10-15/
Merck & Co., Inc. $MRK Stock Position Lessened by HBW Advisory Services LLC
October 15 at 7:19 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-merck-co-inc-mrk-stock-position-lessened-by-hbw-advisory-services-llc-2026-10-15/
Merck & Co., Inc. $MRK Stock: Fort Washington Investment Advisors Inc. OH Decreases Holdings
October 15 at 7:12 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-merck-co-inc-mrk-stock-fort-washington-investment-advisors-inc-oh-decreases-holdings-2026-10-15/
24,447 Shares of Merck & Co., Inc. $MRK Purchased by B.A. Schrock Wealth Management Inc.
October 15 at 7:03 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-24447-shares-of-merck-co-inc-mrk-purchased-by-ba-schrock-wealth-management-inc-2026-10-15/
Merck & Co., Inc. $MRK Stock Acquired by Strategy Asset Managers LLC
October 15 at 4:47 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-merck-co-inc-mrk-stock-acquired-by-strategy-asset-managers-llc-2026-10-15/
Western Financial Corp CA Acquires 29,043 Shares of Merck & Co., Inc. $MRK
October 15 at 4:47 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-western-financial-corp-ca-acquires-29043-shares-of-merck-co-inc-mrk-2026-10-15/
Merck & Co., Inc. $MRK Shares Sold by Godsey & Gibb Inc.
October 15 at 4:08 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-merck-co-inc-mrk-shares-sold-by-godsey-gibb-inc-2026-10-15/
Merck & Co., Inc. $MRK Stock: Cliftonlarsonallen Wealth Advisors LLC Cuts Holdings
October 15 at 3:11 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-merck-co-inc-mrk-stock-cliftonlarsonallen-wealth-advisors-llc-cuts-holdings-2026-10-15/
Merck & Co., Inc. (NYSE:MRK) Stock Jumps 3.6% - Still a Buy?
October 14 at 2:20 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-merck-co-inc-nyse-mrk-stock-jumps-36-still-a-buy-2026-10-14/
Will Keytruda Continue to Aid Merck's Top Line in Q3 Earnings?
October 14 at 1:35 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/keytruda-continue-aid-mercks-top-134600560.html
Merck CEO tells CNBC he expects breakthrough cancer vaccine will become faster to make
October 14 at 1:24 PM  |  cnbc.comhttps://www.cnbc.com/2026/10/14/merck-moderna-cancer-vaccine-manufacturing-time.html
Will Keytruda Continue to Aid Merck's Top Line in Q3 Earnings?
October 14 at 11:51 AM  |  zacks.comhttps://www.zacks.com/stock/news/3007121/will-keytruda-continue-to-aid-merck-s-top-line-in-q3-earnings?cid=cs-stocknewsapi-ft-analyst_blog|quick_take-3007121
Merck & Co., Inc. $MRK Holdings Increased by First Citizens Bank & Trust Co.
October 14 at 7:20 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-merck-co-inc-mrk-holdings-increased-by-first-citizens-bank-trust-co-2026-10-14/
Merck & Co., Inc. $MRK Stock Holdings Cut by Salem Investment Counselors Inc.
October 14 at 4:15 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-merck-co-inc-mrk-stock-holdings-cut-by-salem-investment-counselors-inc-2026-10-14/
Merck & Co., Inc. $MRK Position Cut by Perpetual Ltd
October 14 at 3:36 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-merck-co-inc-mrk-position-cut-by-perpetual-ltd-2026-10-14/
Merck & Company (MRK) Gets a Buy from Leerink Partners
October 13 at 10:07 PM  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/MRK/pressreleases/6702012/merck-company-mrk-gets-a-buy-from-leerink-partners/
Merck (MRK) Dips More Than Broader Market: What You Should Know
October 13 at 10:07 PM  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/merck-mrk-dips-more-broader-205003816.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Micron, Coherent and Tower Semiconductor: 3 Stocks Built on AI's Bottlenecks
NVIDIA Just Named AI's Next Bottleneck—And These 3 Stocks Sit Right In It
By Bridget Bennett | September 20, 2026
Wood-framed house under construction in a residential neighborhood, with lumber stacked nearby and completed homes in the background.
Homebuilders Are Down for the Year, Is Wall Street in Denial?
By Chris Markoch | September 16, 2026
Enterprise Products, Energy Transfer and Williams: 3 AI Power Bottleneck Plays
The AI Bottleneck Is Not Chips Anymore and 3 Pipeline Stocks Are Cashing In
By Bridget Bennett | September 20, 2026
Micron logo on a silicon wafer, highlighting MU memory-chip demand driven by AI and data-center spending.
Micron’s AI Memory Boom Could Send Shares 100% Higher
By Thomas Hughes | September 16, 2026
Woman wearing an Oura ring holds a coffee cup at an outdoor table with a city skyline behind her.
Oura’s $15.6 Billion IPO Is Betting Investors See More Than a Smart Ring
By Jeffrey Neal Johnson | September 22, 2026
Bay National stock logo

Bay National OTCMKTS:BAYN

$0.01 0.00 (0.00%)
As of 07/21/2021

Bay National Corp. operates as a bank holding company. It offers loans, deposits, investments and other banking and financial services through its subsidiary, Bay National Bank. The company was founded in 1999 and is headquartered in Lutherville, MD.

GENFIT stock logo

GENFIT NASDAQ:GNFT

Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.

MorphoSys stock logo

MorphoSys NASDAQ:MOR

$18.96 0.00 (0.00%)
As of 10/14/2026

MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.

Merck & Co., Inc. stock logo

Merck & Co., Inc. NYSE:MRK

$147.01 -0.36 (-0.24%)
As of 03:00 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas